Akt3/CDK4/cdc25b inhibitors (Johnson & Johnson)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameAkt3/CDK4/cdc25b inhibitors (Johnson & Johnson)
Drug Alias Nameprotein kinase B/cyclin D1/phosphatase cdc25b inhibitors (Johnson & Johnson)JNJ-17286009-AACJNJ-17287842-AAA
ClassificationSmall molecules
Mechanisms of ActionM-phase inducer phosphatase 2 inhibitorsCyclin-dependent kinase 4 inhibitorsAnticancer protein kinase inhibitors +[4] 
TargetsM-phase inducer phosphatase 2Cyclin-dependent kinase 4Serine/threonine-protein kinase AKT3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgium
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson Pharmaceutical Research & Development LLC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJohnson & Johnson Pharmaceutical Research & Development LLC
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A